Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenflow Biosci Regulatory News (GENF)

Share Price Information for Genflow Biosci (GENF)

Share Price is delayed by 15 minutes
Get Live Data
2.025    -0.05 (-2.41%)
Bid:
1.95
Ask:
2.10
Spread: 0.15 (7.692%)
Market Cap: £11.47m
GENF Live PriceLast checked at - London Stock Exchange

Intraday Genflow Biosci Share Chart

Suspension - GENFLOW BIOSCIENCES PLC

1 May 2024 07:30

RNS Number : 6542M
Official List
01 May 2024
 

NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST

01/05/2024 07:30

TEMPORARY SUSPENSION

GENFLOW BIOSCIENCES PLC

The Financial Conduct Authority ("the FCA") temporarily suspends the securities set out below from the Official List effective from 01/05/2024 07:30 at the request of the company:

Security Description

Listing Category

ISIN

Ordinary Shares of GBP0.0003 each;

fully paid

Standard Shares

GB00BP2C3V08 ● 

This notice has been issued by Issuer Management - 020 7066 8352.

NotesSEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.●Denotes the security is being admitted to trading on the London Stock Exchange, a Recognised Investment Exchange.†Denotes the security is also being admitted to trading on Aquis Stock Exchange, a Recognised Investment Exchange.#Denotes the security is also being admitted to trading on Euronext, a Recognised Investment Exchange. Denotes the security is also being admitted to trading on Cboe Europe, a Recognised Investment Exchange.^Denotes the security is also being admitted to trading on Shanghai-London Stock Connect, a Recognised Investment Exchange.*Denotes the security is also being admitted to trading on IPSX Prime, a Recognised Investment Exchange.Notices issued by the FCA in respect of admission of securities to the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange in respect of admission of securities to trading on its markets.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SUSEADLEDFDLEFA
Date   Source Headline
17th Jun 20267:00 amRNSCompany to present at Animal Longevity Summit 2026
4th Jun 20267:00 amRNSNotice of AGM
8th May 202610:07 amRNSExercise of Warrants and Issue of Equity
30th Apr 20261:12 pmRNSFinal Results
28th Apr 20267:00 amRNSExpansion of Confidentiality Agreements
20th Apr 20267:00 amRNS-RStrategic Technology Collaboration
13th Apr 20267:00 amRNSInternational Patent Publication
8th Apr 20268:55 amRNS-RUpdate on the Dog Study
31st Mar 20267:00 amRNSTotal Voting Rights
5th Mar 202610:55 amRNSIssue of Equity & PDMR Notifications
2nd Mar 202612:30 pmRNSResult of GM
2nd Mar 20267:00 amRNSReceipt of First Tranche of Grant
12th Feb 20267:00 amRNSPreliminary Interim Results From Dog Study
11th Feb 20267:00 amRNSNotice of GM
30th Jan 202612:29 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNSAdministrative Approval of Grant & 2026 Priorities
19th Jan 20267:00 amRNSDirectorate change
8th Jan 20267:00 amRNS-RReview of 2025
16th Dec 20257:00 amRNSCompletion of Dosing Phase of Canine Gene Therapy
11th Dec 20257:00 amRNS-RGenflow to Attend Healthcare Conference
31st Oct 20257:00 amRNSTotal Voting Rights
24th Oct 20257:00 amRNSHolding(s) in Company
22nd Oct 20257:00 amRNSSecond European Patent Application
20th Oct 20257:00 amRNSRecognition of Patentability of Claims
10th Oct 20257:00 amRNSUpdate on Animal Health Program
9th Oct 20257:00 amRNSUpdate, Equity Issue and PDMR Notification
2nd Oct 202512:37 pmRNSIssue of Equity - Correction
2nd Oct 20257:59 amRNSIssue of Equity
30th Sep 20257:00 amRNSHalf-year Report
19th Sep 202512:40 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNS-RGenflow Strengthens IP Portfolio
15th Sep 20257:00 amRNS-RGenflow Signs CDAs with Animal Health Companies
27th Aug 20253:07 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNS-RCompany Update on Dog Trials
24th Jul 20257:00 amRNS-RClinical Readiness Acceleration
17th Jul 20257:00 amRNSGenflow Confirms Progression of Grant
17th Jun 20257:00 amRNS-RCorporate Update
12th Jun 202510:16 amRNSResult of AGM
30th May 20253:20 pmRNSTotal Voting Rights
28th May 20257:00 amRNS-RGenflow Signs Master Services Agreement
22nd May 202510:51 amRNSAGM Notice
15th May 20257:00 amRNS-RKey SIRT6 Patent Application
12th May 202510:50 amRNSHolding(s) in Company
9th May 20257:00 amRNSShare Subscription, Director's Dealing and Update
30th Apr 20253:29 pmRNSFinal Results
14th Apr 20257:00 amRNS-RLaunch of AI-Powered Partnership
10th Apr 20257:00 amRNS-RGenflow Launches New Development Program
28th Mar 20257:10 amRNSHolding in Company
28th Mar 20257:00 amRNSDirector Dealings
26th Mar 20257:00 amRNSInstitutional Investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.